Focusing on transformative innovation that benefits patients
Immunocore is a commercial-stage biotechnology company that discovered, developed and commercialized the world’s first approved T cell receptor (TCR) therapy.
Our mission is to radically improve outcomes for patients with cancer, infectious diseases, and autoimmune diseases, by pioneering and delivering transformative immunomodulating medicines.
Built on our proprietary ImmTAX platform, we have a diverse pipeline of bispecific therapies across a broad range of indications, including multiple cancers, HIV and HBV.